Dr. Reddy's Labs launches Fesoterodine Fumarate Extended-Release Tablets in the U.S. market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") announces the launch of Dr. Reddy's Fesoterodine Fumarate Extended-Release Tablets, a therapeutic generic equivalent to Toviaz® (fesoterodine fumarate) Extended-Release Tablets in the U.S. market following the approval by the U.S. Food and Drug Administration (USFDA).

The Toviaz® brand had U.S. sales of approximately $211 million MAT for the most recent twelve months ending in May 2022 according to IQVIA*.

Dr. Reddy's Fesoterodine Fumarate Extended-Release Tablets are available in 4 mg and 8 mg Tablets, each in bottle count sizes of 30.

Shares of Dr. Reddy's Laboratories Limited was last trading in BSE at Rs. 4403.50 as compared to the previous close of Rs. 4338.35. The total number of shares traded during the day was 16354 in over 2310 trades.

The stock hit an intraday high of Rs. 4412.00 and intraday low of 4301.15. The net turnover during the day was Rs. 71512483.00.

Source : Equity Bulls

Keywords

DrReddysLaboratories INE089A01023 FesoterodineFumarate ExtendedReleaseTablets USMarket USFDAApproval